TGFBR1 and chronic kidney disease: FXR activation increases the miR-135a-5p expression, thereby inhibiting the activation of the TGFBR1/TAK1 pathway, and resulting in the attenuation of vascular inflammation and calcification in CKD rats without repairing kidney failure.